Company intelligence / Profile preview

Shanghai Jingze Biotechnology

Ownership: Private
Development stage: Other

Overview

Shanghai Jingze Biotechnology specializes in the R&D and large-scale production of biopharmaceuticals with a focus on biosimilars and innovative biologics. Its lead aflibercept biosimilar has reached Phase III clinical trials for diabetic macular oedema. The company also develops recombinant hormones for reproductive medicine and other biological drugs targeting ophthalmology and ART. Several programs are in clinical or preclinical stages.

Therapeutic areas: OphthalmologyMen's HealthWomen's Health
Modalities: Biological productsBiosimilarFc fusion proteinMonoclonal antibodyHormoneSmall interfering RNA (siRNA)Recombinant protein
Industry: Biotech

Partnerships

Jiangsu Jingze Biomedical Co Ltd

Beyond the preview

Go deeper on Shanghai Jingze Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Jingze Biotechnology.